| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intermittent Claudication | 107 | 2023 | 117 | 22.090 |
Why?
|
| Peripheral Arterial Disease | 52 | 2023 | 144 | 19.240 |
Why?
|
| Walking | 67 | 2023 | 136 | 12.400 |
Why?
|
| Exercise Tolerance | 36 | 2020 | 82 | 8.220 |
Why?
|
| Exercise Therapy | 31 | 2023 | 84 | 7.770 |
Why?
|
| Exercise | 45 | 2023 | 498 | 5.920 |
Why?
|
| Peripheral Vascular Diseases | 39 | 2010 | 64 | 5.830 |
Why?
|
| Exercise Test | 74 | 2023 | 249 | 5.380 |
Why?
|
| Aged | 151 | 2025 | 5599 | 4.720 |
Why?
|
| Oxygen Consumption | 44 | 2020 | 190 | 4.480 |
Why?
|
| Quality of Life | 19 | 2022 | 521 | 4.090 |
Why?
|
| Metabolic Syndrome | 9 | 2025 | 80 | 3.460 |
Why?
|
| Leg | 32 | 2023 | 134 | 3.370 |
Why?
|
| Middle Aged | 110 | 2025 | 7416 | 3.290 |
Why?
|
| Ankle Brachial Index | 19 | 2022 | 34 | 3.190 |
Why?
|
| Male | 151 | 2025 | 13943 | 3.190 |
Why?
|
| Humans | 191 | 2025 | 28896 | 2.910 |
Why?
|
| Female | 135 | 2025 | 15646 | 2.830 |
Why?
|
| Walk Test | 11 | 2020 | 20 | 2.830 |
Why?
|
| Blood Pressure | 37 | 2020 | 357 | 2.580 |
Why?
|
| Muscle, Skeletal | 15 | 2022 | 641 | 2.490 |
Why?
|
| Time Factors | 39 | 2021 | 1613 | 2.370 |
Why?
|
| Lower Extremity | 8 | 2020 | 85 | 2.370 |
Why?
|
| Arteries | 10 | 2014 | 66 | 2.300 |
Why?
|
| Oxygen | 10 | 2019 | 237 | 2.280 |
Why?
|
| Oxidative Stress | 11 | 2019 | 677 | 2.190 |
Why?
|
| Cross-Sectional Studies | 31 | 2025 | 996 | 2.030 |
Why?
|
| Home Care Services | 7 | 2019 | 39 | 1.950 |
Why?
|
| Activities of Daily Living | 15 | 2018 | 106 | 1.890 |
Why?
|
| Inflammation Mediators | 5 | 2019 | 169 | 1.870 |
Why?
|
| Arterial Occlusive Diseases | 17 | 2002 | 44 | 1.690 |
Why?
|
| Aged, 80 and over | 39 | 2021 | 2065 | 1.650 |
Why?
|
| Inflammation | 8 | 2022 | 668 | 1.630 |
Why?
|
| Body Mass Index | 22 | 2021 | 412 | 1.590 |
Why?
|
| Ischemia | 8 | 2019 | 83 | 1.590 |
Why?
|
| Health Status | 7 | 2020 | 149 | 1.550 |
Why?
|
| Surveys and Questionnaires | 27 | 2020 | 1002 | 1.540 |
Why?
|
| Muscle Contraction | 5 | 2020 | 171 | 1.420 |
Why?
|
| Motor Activity | 11 | 2015 | 148 | 1.360 |
Why?
|
| Risk Factors | 32 | 2024 | 2127 | 1.350 |
Why?
|
| Endothelial Cells | 4 | 2019 | 373 | 1.340 |
Why?
|
| Minimal Clinically Important Difference | 2 | 2022 | 2 | 1.310 |
Why?
|
| Gait | 6 | 2018 | 61 | 1.260 |
Why?
|
| Radial Artery | 4 | 2011 | 21 | 1.230 |
Why?
|
| Obesity | 9 | 2017 | 701 | 1.180 |
Why?
|
| Blood Glucose | 17 | 2019 | 310 | 1.180 |
Why?
|
| Body Composition | 27 | 2012 | 267 | 1.170 |
Why?
|
| Biomarkers | 11 | 2025 | 777 | 1.150 |
Why?
|
| Severity of Illness Index | 19 | 2018 | 466 | 1.130 |
Why?
|
| Treatment Outcome | 22 | 2023 | 2426 | 1.130 |
Why?
|
| Sex Factors | 15 | 2020 | 469 | 1.130 |
Why?
|
| Diabetes Mellitus | 5 | 2022 | 215 | 1.110 |
Why?
|
| Feeding Behavior | 2 | 2020 | 104 | 1.100 |
Why?
|
| Ankle | 16 | 2012 | 20 | 1.080 |
Why?
|
| Brachial Artery | 17 | 2010 | 37 | 1.070 |
Why?
|
| C-Reactive Protein | 4 | 2022 | 94 | 1.050 |
Why?
|
| Physical Exertion | 9 | 2007 | 104 | 1.040 |
Why?
|
| Oklahoma | 13 | 2019 | 1053 | 1.030 |
Why?
|
| Smoking | 11 | 2010 | 478 | 1.010 |
Why?
|
| Hemodynamics | 13 | 2011 | 221 | 0.970 |
Why?
|
| Mobility Limitation | 5 | 2020 | 15 | 0.960 |
Why?
|
| Antioxidants | 3 | 2017 | 224 | 0.960 |
Why?
|
| Elasticity | 5 | 2012 | 54 | 0.950 |
Why?
|
| Carotenoids | 1 | 2025 | 5 | 0.950 |
Why?
|
| Age Factors | 17 | 2016 | 737 | 0.950 |
Why?
|
| Comorbidity | 10 | 2023 | 261 | 0.920 |
Why?
|
| Actigraphy | 8 | 2020 | 22 | 0.900 |
Why?
|
| Regional Blood Flow | 18 | 2015 | 164 | 0.890 |
Why?
|
| Adult | 35 | 2022 | 8035 | 0.890 |
Why?
|
| Health Behavior | 2 | 2016 | 159 | 0.880 |
Why?
|
| Pain | 14 | 2015 | 258 | 0.880 |
Why?
|
| Hemoglobins | 4 | 2010 | 118 | 0.870 |
Why?
|
| Endothelium, Vascular | 6 | 2016 | 334 | 0.860 |
Why?
|
| Skin | 1 | 2025 | 153 | 0.860 |
Why?
|
| Predictive Value of Tests | 14 | 2020 | 485 | 0.820 |
Why?
|
| Oxyhemoglobins | 3 | 2020 | 10 | 0.820 |
Why?
|
| Linear Models | 12 | 2017 | 202 | 0.810 |
Why?
|
| Prospective Studies | 13 | 2020 | 1280 | 0.810 |
Why?
|
| Microcirculation | 4 | 2020 | 113 | 0.790 |
Why?
|
| Brain Concussion | 3 | 2024 | 53 | 0.790 |
Why?
|
| Football | 3 | 2024 | 72 | 0.770 |
Why?
|
| Body Weight | 7 | 2018 | 250 | 0.750 |
Why?
|
| Reactive Oxygen Species | 4 | 2017 | 292 | 0.750 |
Why?
|
| Energy Metabolism | 13 | 2011 | 216 | 0.740 |
Why?
|
| Recovery of Function | 9 | 2019 | 123 | 0.690 |
Why?
|
| Soccer | 1 | 2021 | 50 | 0.690 |
Why?
|
| Apoptosis | 7 | 2019 | 780 | 0.660 |
Why?
|
| Aging | 15 | 2022 | 1019 | 0.650 |
Why?
|
| Fibrinolysis | 6 | 2015 | 21 | 0.640 |
Why?
|
| African Americans | 2 | 2014 | 352 | 0.630 |
Why?
|
| Adolescent | 22 | 2021 | 3198 | 0.610 |
Why?
|
| Insulin | 12 | 2015 | 325 | 0.610 |
Why?
|
| Angiogenic Proteins | 1 | 2019 | 4 | 0.600 |
Why?
|
| Cardiovascular Diseases | 9 | 2015 | 381 | 0.570 |
Why?
|
| Mental Health | 2 | 2018 | 111 | 0.560 |
Why?
|
| Cholesterol, HDL | 5 | 2013 | 58 | 0.540 |
Why?
|
| Adipose Tissue | 9 | 2012 | 197 | 0.520 |
Why?
|
| Lipids | 5 | 2015 | 220 | 0.520 |
Why?
|
| Cognition | 2 | 2021 | 331 | 0.510 |
Why?
|
| Child | 11 | 2021 | 2292 | 0.510 |
Why?
|
| Athletic Injuries | 4 | 2024 | 122 | 0.500 |
Why?
|
| Galectin 3 | 1 | 2016 | 1 | 0.500 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 303 | 0.500 |
Why?
|
| Compliance | 7 | 2011 | 21 | 0.490 |
Why?
|
| Pain Measurement | 9 | 2012 | 172 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2012 | 125 | 0.470 |
Why?
|
| Heart Rate | 10 | 2020 | 382 | 0.470 |
Why?
|
| Hypertension | 6 | 2010 | 309 | 0.470 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 1032 | 0.470 |
Why?
|
| Regression Analysis | 14 | 2007 | 211 | 0.460 |
Why?
|
| Anaerobic Threshold | 2 | 2015 | 19 | 0.460 |
Why?
|
| Case-Control Studies | 10 | 2024 | 739 | 0.460 |
Why?
|
| Cognition Disorders | 2 | 2015 | 186 | 0.450 |
Why?
|
| Analysis of Variance | 10 | 2014 | 391 | 0.450 |
Why?
|
| Overweight | 3 | 2018 | 114 | 0.450 |
Why?
|
| Baltimore | 6 | 2021 | 12 | 0.440 |
Why?
|
| Hypoglycemic Agents | 4 | 2011 | 110 | 0.430 |
Why?
|
| Chi-Square Distribution | 5 | 2012 | 145 | 0.410 |
Why?
|
| Monitoring, Ambulatory | 5 | 2011 | 26 | 0.400 |
Why?
|
| Apolipoproteins | 1 | 2013 | 21 | 0.400 |
Why?
|
| Risk Assessment | 8 | 2013 | 631 | 0.390 |
Why?
|
| Prevalence | 5 | 2021 | 518 | 0.380 |
Why?
|
| Blood Circulation | 3 | 2004 | 13 | 0.380 |
Why?
|
| Cardiovascular System | 2 | 2014 | 41 | 0.380 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 179 | 0.380 |
Why?
|
| Postural Balance | 4 | 2009 | 41 | 0.370 |
Why?
|
| Physical Endurance | 6 | 2001 | 91 | 0.370 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 302 | 0.370 |
Why?
|
| Energy Intake | 3 | 2013 | 69 | 0.370 |
Why?
|
| Young Adult | 9 | 2021 | 2839 | 0.370 |
Why?
|
| Patients | 1 | 2011 | 17 | 0.360 |
Why?
|
| Leisure Activities | 2 | 2006 | 16 | 0.360 |
Why?
|
| Memory, Short-Term | 2 | 2022 | 64 | 0.360 |
Why?
|
| Hypercholesterolemia | 2 | 2008 | 18 | 0.350 |
Why?
|
| Pulsatile Flow | 2 | 2008 | 9 | 0.350 |
Why?
|
| Accidental Falls | 2 | 2001 | 32 | 0.350 |
Why?
|
| Blood Coagulation | 2 | 2014 | 120 | 0.340 |
Why?
|
| Cardiovascular Agents | 1 | 2011 | 22 | 0.340 |
Why?
|
| Angina Pectoris | 1 | 2011 | 109 | 0.330 |
Why?
|
| Nutritional Status | 1 | 2011 | 80 | 0.330 |
Why?
|
| Neuropsychological Tests | 3 | 2021 | 249 | 0.330 |
Why?
|
| Cells, Cultured | 3 | 2019 | 1022 | 0.320 |
Why?
|
| Health Status Disparities | 1 | 2010 | 66 | 0.300 |
Why?
|
| Fitness Trackers | 2 | 2020 | 11 | 0.300 |
Why?
|
| Prognosis | 4 | 2021 | 811 | 0.290 |
Why?
|
| Blood Gas Monitoring, Transcutaneous | 5 | 1997 | 5 | 0.290 |
Why?
|
| Conservation of Natural Resources | 2 | 2019 | 34 | 0.280 |
Why?
|
| Blood Pressure Determination | 4 | 2007 | 27 | 0.280 |
Why?
|
| Patient Compliance | 3 | 2014 | 76 | 0.280 |
Why?
|
| Vascular Stiffness | 2 | 2020 | 41 | 0.270 |
Why?
|
| Biodiversity | 2 | 2019 | 114 | 0.270 |
Why?
|
| Oral Surgical Procedures | 1 | 2007 | 6 | 0.270 |
Why?
|
| International Normalized Ratio | 1 | 2007 | 27 | 0.270 |
Why?
|
| Head | 2 | 2024 | 19 | 0.270 |
Why?
|
| Hyperglycemia | 1 | 2008 | 78 | 0.260 |
Why?
|
| Vasomotor System | 1 | 2006 | 8 | 0.260 |
Why?
|
| Warfarin | 1 | 2007 | 94 | 0.260 |
Why?
|
| Indians, North American | 1 | 2011 | 544 | 0.250 |
Why?
|
| Adiposity | 3 | 2013 | 94 | 0.250 |
Why?
|
| Systole | 5 | 2012 | 24 | 0.250 |
Why?
|
| Geriatric Assessment | 4 | 2017 | 91 | 0.240 |
Why?
|
| Sex Characteristics | 6 | 2015 | 175 | 0.240 |
Why?
|
| Arteriosclerosis | 3 | 2004 | 30 | 0.240 |
Why?
|
| beta Carotene | 1 | 2025 | 5 | 0.240 |
Why?
|
| Monitoring, Physiologic | 2 | 2014 | 58 | 0.230 |
Why?
|
| Vegetables | 1 | 2025 | 29 | 0.230 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 226 | 0.230 |
Why?
|
| Fruit | 1 | 2025 | 40 | 0.230 |
Why?
|
| Body Height | 3 | 2018 | 57 | 0.230 |
Why?
|
| NF-kappa B | 2 | 2017 | 191 | 0.230 |
Why?
|
| Pilot Projects | 3 | 2021 | 464 | 0.230 |
Why?
|
| Sex Distribution | 3 | 2012 | 78 | 0.230 |
Why?
|
| Rest | 8 | 2013 | 96 | 0.230 |
Why?
|
| Anticoagulants | 1 | 2007 | 297 | 0.230 |
Why?
|
| Anthropometry | 4 | 2018 | 93 | 0.220 |
Why?
|
| Reproducibility of Results | 10 | 2021 | 787 | 0.220 |
Why?
|
| Life Style | 4 | 2018 | 91 | 0.220 |
Why?
|
| Insulin Resistance | 2 | 2016 | 176 | 0.210 |
Why?
|
| Mouth Protectors | 1 | 2024 | 2 | 0.210 |
Why?
|
| Acceleration | 1 | 2024 | 17 | 0.210 |
Why?
|
| Cholesterol, LDL | 5 | 2013 | 64 | 0.210 |
Why?
|
| Logistic Models | 3 | 2024 | 410 | 0.200 |
Why?
|
| Resistance Training | 2 | 2016 | 212 | 0.190 |
Why?
|
| Pulse Wave Analysis | 1 | 2022 | 30 | 0.190 |
Why?
|
| American Heart Association | 2 | 2019 | 21 | 0.190 |
Why?
|
| Executive Function | 1 | 2022 | 27 | 0.190 |
Why?
|
| Models, Statistical | 3 | 2018 | 128 | 0.180 |
Why?
|
| Medicare | 1 | 2022 | 126 | 0.180 |
Why?
|
| Neck | 1 | 2021 | 26 | 0.180 |
Why?
|
| Australia | 1 | 2021 | 40 | 0.180 |
Why?
|
| United Arab Emirates | 2 | 2019 | 3 | 0.180 |
Why?
|
| Diet | 5 | 2018 | 241 | 0.170 |
Why?
|
| Cause of Death | 1 | 2021 | 73 | 0.170 |
Why?
|
| United States | 6 | 2022 | 2226 | 0.170 |
Why?
|
| Muscle Weakness | 1 | 2001 | 16 | 0.170 |
Why?
|
| Triglycerides | 5 | 2013 | 123 | 0.170 |
Why?
|
| Calorimetry, Indirect | 3 | 1998 | 15 | 0.160 |
Why?
|
| Popliteal Artery | 3 | 2001 | 10 | 0.160 |
Why?
|
| Recommended Dietary Allowances | 1 | 2020 | 6 | 0.160 |
Why?
|
| Mass Screening | 1 | 2021 | 158 | 0.160 |
Why?
|
| Femoral Artery | 3 | 2001 | 58 | 0.160 |
Why?
|
| Neurovascular Coupling | 1 | 2022 | 154 | 0.160 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2012 | 75 | 0.160 |
Why?
|
| Body Fat Distribution | 2 | 2011 | 15 | 0.150 |
Why?
|
| Disease Progression | 5 | 2010 | 477 | 0.150 |
Why?
|
| Endangered Species | 1 | 2019 | 7 | 0.150 |
Why?
|
| Lizards | 1 | 2019 | 12 | 0.150 |
Why?
|
| Cohort Studies | 5 | 2021 | 897 | 0.150 |
Why?
|
| Menopause | 2 | 1995 | 30 | 0.150 |
Why?
|
| Kinesiology, Applied | 1 | 1998 | 1 | 0.140 |
Why?
|
| Ultrasonography, Doppler | 3 | 2007 | 22 | 0.140 |
Why?
|
| Biological Evolution | 1 | 2019 | 101 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 409 | 0.140 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 271 | 0.140 |
Why?
|
| Reptiles | 1 | 2018 | 2 | 0.140 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2018 | 14 | 0.140 |
Why?
|
| Trees | 1 | 2018 | 47 | 0.140 |
Why?
|
| Neovascularization, Physiologic | 1 | 2019 | 124 | 0.140 |
Why?
|
| Wasting Syndrome | 1 | 2018 | 7 | 0.140 |
Why?
|
| Autism Spectrum Disorder | 1 | 2018 | 25 | 0.140 |
Why?
|
| Child Nutrition Disorders | 1 | 2018 | 6 | 0.140 |
Why?
|
| Adenosine Diphosphate | 1 | 1997 | 27 | 0.140 |
Why?
|
| Incidence | 2 | 2014 | 572 | 0.140 |
Why?
|
| Educational Status | 1 | 2018 | 112 | 0.130 |
Why?
|
| Sarcopenia | 1 | 2017 | 44 | 0.130 |
Why?
|
| Hydroxyl Radical | 1 | 2017 | 7 | 0.130 |
Why?
|
| Community Health Services | 1 | 2017 | 33 | 0.130 |
Why?
|
| Anxiety | 1 | 2018 | 158 | 0.130 |
Why?
|
| Phylogeny | 1 | 2019 | 494 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 261 | 0.130 |
Why?
|
| Parents | 1 | 2018 | 133 | 0.130 |
Why?
|
| Cell Culture Techniques | 1 | 2017 | 117 | 0.130 |
Why?
|
| Galectins | 1 | 2016 | 2 | 0.120 |
Why?
|
| Hot Temperature | 1 | 1997 | 87 | 0.120 |
Why?
|
| Biomechanical Phenomena | 2 | 2024 | 182 | 0.120 |
Why?
|
| Osteoarthritis, Hip | 1 | 2016 | 12 | 0.120 |
Why?
|
| Transfection | 1 | 2017 | 319 | 0.120 |
Why?
|
| Muscle Strength | 2 | 2016 | 230 | 0.120 |
Why?
|
| Disability Evaluation | 2 | 2017 | 54 | 0.120 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2016 | 29 | 0.120 |
Why?
|
| Plethysmography | 3 | 2006 | 27 | 0.120 |
Why?
|
| Blood Proteins | 1 | 2016 | 68 | 0.120 |
Why?
|
| AIDS Vaccines | 1 | 2015 | 4 | 0.120 |
Why?
|
| HLA-A2 Antigen | 1 | 2015 | 18 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2016 | 237 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2015 | 50 | 0.120 |
Why?
|
| Fibrosis | 1 | 2016 | 143 | 0.120 |
Why?
|
| Absorptiometry, Photon | 3 | 2012 | 101 | 0.120 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2015 | 46 | 0.120 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2015 | 100 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2016 | 247 | 0.110 |
Why?
|
| Tissue Plasminogen Activator | 4 | 2004 | 36 | 0.110 |
Why?
|
| Vascular Resistance | 2 | 2008 | 50 | 0.110 |
Why?
|
| Vascular Patency | 1 | 2014 | 44 | 0.110 |
Why?
|
| Hemoglobinometry | 1 | 2014 | 5 | 0.110 |
Why?
|
| Heart Diseases | 3 | 2000 | 71 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2009 | 2635 | 0.110 |
Why?
|
| Infant | 1 | 2018 | 1026 | 0.110 |
Why?
|
| Reference Values | 1 | 2014 | 200 | 0.110 |
Why?
|
| Probability | 2 | 2005 | 78 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2018 | 1174 | 0.110 |
Why?
|
| Eating | 2 | 2013 | 71 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2014 | 54 | 0.100 |
Why?
|
| Interleukin-8 | 1 | 2013 | 45 | 0.100 |
Why?
|
| Physical Fitness | 4 | 2000 | 62 | 0.100 |
Why?
|
| HIV Infections | 1 | 2015 | 165 | 0.100 |
Why?
|
| Hematoma, Subdural, Chronic | 1 | 2013 | 8 | 0.100 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 23 | 0.100 |
Why?
|
| Accelerometry | 1 | 2013 | 13 | 0.100 |
Why?
|
| Hyperemia | 3 | 2004 | 40 | 0.100 |
Why?
|
| Lipoproteins, LDL | 1 | 2013 | 42 | 0.100 |
Why?
|
| Brain Ischemia | 2 | 2004 | 87 | 0.100 |
Why?
|
| Postprandial Period | 1 | 2013 | 51 | 0.100 |
Why?
|
| Manometry | 1 | 2012 | 36 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 77 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 251 | 0.090 |
Why?
|
| Ultrasonography | 2 | 2011 | 243 | 0.090 |
Why?
|
| Foot | 3 | 2001 | 23 | 0.090 |
Why?
|
| Vasodilation | 3 | 2002 | 115 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 524 | 0.090 |
Why?
|
| Coronary Artery Disease | 2 | 2011 | 220 | 0.090 |
Why?
|
| Dietary Fiber | 1 | 2011 | 6 | 0.090 |
Why?
|
| Puberty | 1 | 2011 | 13 | 0.090 |
Why?
|
| Dietary Carbohydrates | 1 | 2011 | 26 | 0.090 |
Why?
|
| Fats | 3 | 1996 | 6 | 0.090 |
Why?
|
| Iliac Artery | 1 | 1991 | 19 | 0.090 |
Why?
|
| Dietary Proteins | 1 | 2011 | 35 | 0.090 |
Why?
|
| Blood Flow Velocity | 3 | 2007 | 66 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2011 | 60 | 0.080 |
Why?
|
| Obesity, Abdominal | 1 | 2010 | 4 | 0.080 |
Why?
|
| Fasting | 5 | 2000 | 91 | 0.080 |
Why?
|
| Postmenopause | 1 | 2010 | 84 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2010 | 66 | 0.080 |
Why?
|
| Critical Illness | 1 | 2010 | 66 | 0.080 |
Why?
|
| Catheterization | 1 | 2009 | 50 | 0.080 |
Why?
|
| Health Promotion | 1 | 2011 | 179 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 82 | 0.080 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 2 | 2009 | 4 | 0.070 |
Why?
|
| Sympathetic Nervous System | 4 | 1998 | 68 | 0.070 |
Why?
|
| Forecasting | 3 | 2000 | 76 | 0.070 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 3 | 2004 | 20 | 0.070 |
Why?
|
| Body Constitution | 3 | 1997 | 11 | 0.070 |
Why?
|
| Chronic Disease | 3 | 2011 | 274 | 0.070 |
Why?
|
| Adaptation, Physiological | 1 | 2009 | 173 | 0.070 |
Why?
|
| Vasodilator Agents | 1 | 2008 | 79 | 0.070 |
Why?
|
| Abdominal Fat | 1 | 2008 | 17 | 0.070 |
Why?
|
| Dyslipidemias | 1 | 2008 | 33 | 0.070 |
Why?
|
| Brazil | 2 | 2020 | 24 | 0.070 |
Why?
|
| Minor Surgical Procedures | 1 | 2007 | 1 | 0.070 |
Why?
|
| Waist-Hip Ratio | 1 | 2007 | 9 | 0.070 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2007 | 7 | 0.070 |
Why?
|
| Acoustics | 1 | 2007 | 10 | 0.070 |
Why?
|
| Tooth Extraction | 1 | 2007 | 16 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 194 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2007 | 38 | 0.060 |
Why?
|
| Abdomen | 1 | 2007 | 41 | 0.060 |
Why?
|
| Role | 1 | 2006 | 6 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2006 | 20 | 0.060 |
Why?
|
| Patient Selection | 2 | 2013 | 150 | 0.060 |
Why?
|
| Residence Characteristics | 2 | 2015 | 105 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 344 | 0.060 |
Why?
|
| Respiratory Function Tests | 2 | 1996 | 27 | 0.060 |
Why?
|
| Sports Equipment | 1 | 2024 | 5 | 0.060 |
Why?
|
| Emotions | 1 | 2006 | 138 | 0.060 |
Why?
|
| Tibial Arteries | 1 | 2004 | 3 | 0.050 |
Why?
|
| Paresis | 1 | 2004 | 9 | 0.050 |
Why?
|
| Physical Education and Training | 2 | 1995 | 48 | 0.050 |
Why?
|
| Posture | 1 | 2004 | 39 | 0.050 |
Why?
|
| Craniocerebral Trauma | 1 | 2024 | 27 | 0.050 |
Why?
|
| Calorimetry | 3 | 1998 | 12 | 0.050 |
Why?
|
| Coronary Disease | 2 | 2001 | 120 | 0.050 |
Why?
|
| Age Distribution | 1 | 2002 | 73 | 0.050 |
Why?
|
| Norepinephrine | 4 | 1998 | 32 | 0.050 |
Why?
|
| Basal Metabolism | 4 | 1996 | 11 | 0.050 |
Why?
|
| Arterioles | 1 | 2022 | 61 | 0.050 |
Why?
|
| Plasminogen Inactivators | 1 | 2001 | 1 | 0.040 |
Why?
|
| Electron Transport Complex III | 1 | 2001 | 3 | 0.040 |
Why?
|
| NADH Dehydrogenase | 1 | 2001 | 6 | 0.040 |
Why?
|
| Foot Ulcer | 1 | 2001 | 2 | 0.040 |
Why?
|
| Gangrene | 1 | 2001 | 4 | 0.040 |
Why?
|
| Algorithms | 1 | 2024 | 431 | 0.040 |
Why?
|
| Hip | 1 | 2001 | 12 | 0.040 |
Why?
|
| Knee | 1 | 2001 | 25 | 0.040 |
Why?
|
| Stroke | 1 | 2004 | 261 | 0.040 |
Why?
|
| Thyroid Hormones | 4 | 1995 | 37 | 0.040 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2001 | 37 | 0.040 |
Why?
|
| Hospitals, Veterans | 1 | 2000 | 22 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2022 | 224 | 0.040 |
Why?
|
| Geriatrics | 1 | 2000 | 47 | 0.040 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 1998 | 22 | 0.040 |
Why?
|
| Cholesterol | 2 | 2000 | 203 | 0.040 |
Why?
|
| Organization and Administration | 1 | 2019 | 1 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 14 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2019 | 33 | 0.040 |
Why?
|
| Animals | 3 | 2019 | 10703 | 0.040 |
Why?
|
| Species Specificity | 1 | 2019 | 195 | 0.040 |
Why?
|
| Consensus | 1 | 2019 | 76 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 218 | 0.040 |
Why?
|
| Body Water | 1 | 1998 | 19 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2000 | 429 | 0.040 |
Why?
|
| Oman | 1 | 2018 | 1 | 0.040 |
Why?
|
| Health Surveys | 1 | 2018 | 85 | 0.040 |
Why?
|
| Forests | 1 | 2018 | 37 | 0.040 |
Why?
|
| Climate | 1 | 2018 | 33 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 245 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2017 | 8 | 0.030 |
Why?
|
| Independent Living | 1 | 2017 | 14 | 0.030 |
Why?
|
| Arm | 1 | 1997 | 37 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 1998 | 379 | 0.030 |
Why?
|
| Mitochondria | 1 | 2001 | 410 | 0.030 |
Why?
|
| Electrodes | 1 | 1997 | 72 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 1998 | 152 | 0.030 |
Why?
|
| Skinfold Thickness | 2 | 1993 | 19 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 46 | 0.030 |
Why?
|
| Physical Therapy Modalities | 1 | 2016 | 44 | 0.030 |
Why?
|
| Ecosystem | 1 | 2018 | 229 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1996 | 115 | 0.030 |
Why?
|
| HIV-1 | 1 | 2015 | 59 | 0.030 |
Why?
|
| Diastole | 1 | 1995 | 22 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 98 | 0.030 |
Why?
|
| Oxidation-Reduction | 4 | 1998 | 381 | 0.030 |
Why?
|
| Platelet Function Tests | 1 | 2014 | 24 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 2014 | 44 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 513 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 1993 | 18 | 0.030 |
Why?
|
| Third-Party Consent | 1 | 2013 | 1 | 0.030 |
Why?
|
| Neuroendoscopy | 1 | 2013 | 14 | 0.030 |
Why?
|
| Weight-Bearing | 1 | 1993 | 43 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2013 | 17 | 0.020 |
Why?
|
| Craniotomy | 1 | 2013 | 61 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2013 | 95 | 0.020 |
Why?
|
| Random Allocation | 1 | 1993 | 151 | 0.020 |
Why?
|
| Weight Lifting | 1 | 1992 | 49 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 100 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 46 | 0.020 |
Why?
|
| Apolipoprotein C-III | 1 | 2010 | 12 | 0.020 |
Why?
|
| Public Health | 1 | 2011 | 97 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2009 | 20 | 0.020 |
Why?
|
| Angioplasty, Laser | 1 | 2009 | 1 | 0.020 |
Why?
|
| Atherectomy | 1 | 2009 | 11 | 0.020 |
Why?
|
| Angioplasty, Balloon | 1 | 2009 | 21 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2009 | 46 | 0.020 |
Why?
|
| Cryosurgery | 1 | 2009 | 19 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2009 | 10 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 56 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 2009 | 54 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2009 | 51 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2009 | 31 | 0.020 |
Why?
|
| Glycated Hemoglobin A | 1 | 2009 | 64 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 2009 | 68 | 0.020 |
Why?
|
| Medicaid | 1 | 2009 | 55 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 224 | 0.020 |
Why?
|
| Stents | 1 | 2009 | 121 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1998 | 257 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 4809 | 0.010 |
Why?
|
| Verbal Learning | 1 | 2003 | 14 | 0.010 |
Why?
|
| Memory | 1 | 2003 | 76 | 0.010 |
Why?
|
| Attention | 1 | 2003 | 91 | 0.010 |
Why?
|
| Viscera | 1 | 2002 | 18 | 0.010 |
Why?
|
| Glucose Intolerance | 1 | 2002 | 24 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2002 | 60 | 0.010 |
Why?
|
| Citrate (si)-Synthase | 1 | 2001 | 23 | 0.010 |
Why?
|
| Electron Transport | 1 | 2001 | 31 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 481 | 0.010 |
Why?
|
| Plasminogen Activators | 1 | 1998 | 7 | 0.010 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 1998 | 13 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 1998 | 46 | 0.010 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1997 | 22 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 1997 | 38 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1997 | 68 | 0.010 |
Why?
|
| Thrombosis | 1 | 1998 | 150 | 0.010 |
Why?
|
| Radioisotope Dilution Technique | 1 | 1996 | 14 | 0.010 |
Why?
|
| Palmitic Acid | 1 | 1996 | 11 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1995 | 25 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 1998 | 351 | 0.010 |
Why?
|
| Palmitates | 1 | 1994 | 9 | 0.010 |
Why?
|
| Kinetics | 1 | 1995 | 553 | 0.010 |
Why?
|
| Mathematics | 1 | 1993 | 42 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1995 | 398 | 0.010 |
Why?
|
| Carbohydrate Metabolism | 1 | 1992 | 30 | 0.010 |
Why?
|
| Tritium | 1 | 1992 | 17 | 0.010 |
Why?
|
| Aerobiosis | 1 | 1992 | 14 | 0.010 |
Why?
|
| Fatty Acids | 1 | 1994 | 221 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1992 | 59 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1992 | 102 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1992 | 79 | 0.010 |
Why?
|
| Lipoproteins | 1 | 1992 | 99 | 0.010 |
Why?
|